Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting

American Journal of Medicine

Volumn 114, Issue 9, 2003, Pages 715-722

  Dibra, Alban ^a   Mehilli, Julinda ^a   Braun, Siegmund ^b   Hadamitzky, Martin ^a   Baum, Hannsjörg ^b   Dirschinger, Josef ^a   Schühlen, Helmut ^a   Schömig, Albert ^a   Kastrati, Adnan ^a,b  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Coronary disease; Inflammation; Restenosis; Stents; Thrombosis

Indexed keywords

C REACTIVE PROTEIN;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY SURGERY; CORONARY STENT; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATION; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION; RESTENOSIS; STABLE ANGINA PECTORIS; TREATMENT OUTCOME;

EID: 0038771932     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9343(03)00183-9     Document Type: Article

References (32)

1. Ridker P.M., Cushman M., Stampfer M.J., et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 336:1997;973-979.
2. Tracy R.P., Lemaitre R.N., Psaty B.M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol. 17:1997;1121-1127.
3. Morrow D.A., Rifai N., Antman E.M., et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes a TIMI 11A substudy. Thrombolysis in Myocardial Infarction . J Am Coll Cardiol. 31:1998;1460-1465.
4. Lagrand W.K., Visser C.A., Hermens W.T., et al. C-reactive protein as a cardiovascular risk factor more than an epiphenomenon? Circulation. 100:1999;96-102.
5. Danesh J., Pepys M.B. C-reactive protein in healthy and in sick populations. Eur Heart J. 21:2000;1564-1565.
6. Liuzzo G., Biasucci L.M., Gallimore J.R., et al. The prognostic value of C-reactive protein and serum amyloid A protein in severe unstable angina. N Engl J Med. 331:1994;417-424.
7. Buffon A., Liuzzo G., Biasucci L.M., et al. Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol. 34:1999;1512-1521.
8. Walter D.H., Fichtlscherer S., Sellwig M., et al. Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol. 37:2001;839-846.
9. Chew D.P., Bhatt D.L., Robbins M.A., et al. Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation. 104:2001;992-997.
10. Mueller C., Buettner H.J., Hodgson J.M., et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation. 105:2002;1412-1415.
11. de Winter R.J., Heyde G.S., Koch K.T., et al. The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J. 23:2002;960-966.
12. Schömig A., Neumann F.J., Kastrati A., et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary artery stents. N Engl J Med. 334:1996;1084-1089.
13. Ellis S.G., Vandormael M.G., Cowley M.J., et al. Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease implications for patient selection . Circulation. 82:1990;1193-1202.
14. Armstrong P.W. Stable ischemic syndromes. Topol E.J. Textbook of Cardiovascular Medicine. 3rd ed:1998;333-364 Lippincott-Raven, Philadelphia, Pennsylvania.
15. Rutherford J.D., Braunwald E., Cohn P.F. Chronic ischemic heart disease. Braunwald E. Heart Disease A Textbook of Cardiovascular Medicine . 3rd ed:1988;1314-1378 W. B. Saunders Company, Philadelphia, Pennsylvania.
16. Randomized placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 352:1998;87-92.
17. Schühlen H., Kastrati A., Dirschinger J., et al. Intracoronary stenting and risk for major adverse cardiac events during the first month. Circulation. 98:1998;104-111.
18. Hutchinson W.L., Koenig W., Frohlich M., et al. Immunoradiometric assay of circulating C-reactive protein age-related values in the adult general population . Clin Chem. 46:2000;934-938.
19. Levinson S.S., Elin R.J. What is C-reactive protein telling us about coronary artery disease? Arch Intern Med. 162:2002;389-392.
20. Walter D.H., Fichtlscherer S., Britten M.B., et al. Statin therapy, inflammation and recurrent coronary events in patients following coronary stent implantation. J Am Coll Cardiol. 38:2001;2006-2012.
21. Ridker P.M. High-sensitivity C-reactive protein potential adjunct for global risk assessment in the primary prevention of cardiovascular disease . Circulation. 103:2001;1813-1818.
22. Mortensen R.F. C-reactive protein, inflammation, and innate immunity. Immunol Res. 24:2001;163-176.
23. Cermak J., Key N.S., Bach R.R., et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood. 82:1993;513-520.
24. Fichtlscherer S., Rosenberger G., Walter D.H., et al. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation. 102:2000;1000-1006.
25. Pasceri V., Willerson J.T., Yeh E.T. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 102:2000;2165-2168.
26. Bhatt D.L., Topol E.J. Need to test the arterial inflammation hypothesis. Circulation. 106:2002;136-140.
27. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels the Pravastatin Inflammation/CRP Evaluation (PRINCE): a randomized trial and cohort study . JAMA. 286:2001;64-70.
28. Chew D.P., Bhatt D.L., Robbins M.A., et al. Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 88:2001;672-674.
29. Doo Y.C., Kim D.M., Oh D.J., et al. Effect of beta blockers on expression of interleukin-6 and C-reactive protein in patients with unstable angina pectoris. Am J Cardiol. 88:2001;422-424.
30. Malik J., Melenovsky V., Wichterle D., et al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (Fenofibrate versus Atorvastatin Trial - FAT). Cardiovasc Res. 52:2001;290-298.
31. Wu L., Iwai M., Nakagami H., et al. Roles of angiotensin II type 2 receptor stimulation associated with selective angiotensin II type 1 receptor blockade with valsartan in the improvement of inflammation-induced vascular injury. Circulation. 104:2001;2716-2721.
32. Riesen W.F., Engler H., Risch M., et al. Short-term effects of atorvastatin on C-reactive protein. Eur Heart J. 23:2002;794-799.